United States - English - NLM (National Library of Medicine)

physicians total care, inc. - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide - unii:8n3dw7272p) - cyclophosphamide 25 mg - cyclophosphamide tablets usp, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible to cyclophosphamide treatment: - malignant lymphomas (stages iii and iv of the ann arbor staging system), hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, burkitt’s lymphoma. - multiple myeloma. - leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). - mycosis fungoides (advanced disease). - neuroblastoma (disseminated disease). - adenocarcinoma of the ovary. - retinoblastoma. - carcinoma of the breast. cyclophosphamide tablets usp, 25 mg and 50 mg are useful in carefully s

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals inc - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide 1 kg in 1 kg

United States - English - NLM (National Library of Medicine)

roxane laboratories, inc. - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide - unii:8n3dw7272p) - tablet - 25 mg - cyclophosphamide tablets, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible to cyclophosphamide treatment: - malignant lymphomas (stages iii and iv of the ann arbor staging system), hodgkin’s disease, lyphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, burkitt’s lymphoma. - multiple myeloma. - leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia; acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). - mycosis fungoides (advanced disease). - neuroblastoma (disseminated disease). - adenocarcinoma of the ovary. - retinoblastoma. - carcinoma of the breast. cyclophosphamide tablets are useful in carefully selected cases of biopsy proven “minimal c

Malta - English - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - cyclophosphamide - powder for solution for injection/infusion - cyclophosphamide 500 mg - antineoplastic agents

Malta - English - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - cyclophosphamide - powder for solution for injection/infusion - cyclophosphamide 1000 mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide anhydrous 500 mg in 25 ml

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide anhydrous 50 mg

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide anhydrous 25 mg - cyclophosphamide capsules are indicated for the treatment of: cyclophosphamide capsules, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. cyclophosphamide capsules are indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. limitations of use: the safety and effectiveness of cyclophosphamide capsules for the treatment of nephrotic syndrome in adults or other renal disease has not been established. cyclophosphamide capsules are contraindicated in patients with: risk summary based on its mechanism of action and published reports of effects in pregnant patients or animals, cyclophosphamide capsules can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1) and nonclinical toxicology (13.1)] . exposure to cyclophosphamide during pregnancy may cause feta

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide anhydrous 500 mg in 25 ml - cyclophosphamide is indicated for the treatment of: cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. cyclophosphamide is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. limitations of use: the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. pregnancy category d risk summary cyclophosphamide can cause fetal harm when administered to a pregnant woman based on its mechanism of action and published reports of effects in pregnant patients or animals. exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn. cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monke

United States - English - NLM (National Library of Medicine)

sandoz inc. - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide anhydrous 500 mg in 25 ml - cyclophosphamide is indicated for the treatment of: - malignant lymphomas (stages iii and iv of the ann arbor staging system), hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, burkitt's lymphoma - multiple myeloma - leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) - mycosis fungoides (advanced disease) - neuroblastoma (disseminated disease) - adenocarcinoma of the ovary - retinoblastoma - carcinoma of the breast cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs.    cyclophosphamide is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately